• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Chemours (CC) Just Gave Investors Something To Think About

    Simply Wall St·11/12/2026 06:27:00
    Listen to the news

    Chemours (CC) has drawn fresh attention after third quarter results showed net income of US$196 million and the launch of Faizeon liquid cooling fluids aimed at AI and high-density data center customers.

    Against that product launch backdrop, Chemours shares change hands at US$13.72, with a 1-day share price return of 1.78% and a 30-day share price gain of 2.46%. However, the 90-day share price return has declined 10.09%, pointing to fading near term momentum after earlier strength. Over a longer horizon, investors have seen an 11.17% total shareholder return over 1 year, set against a 44.34% decline in 3-year total shareholder return and a 50.35% drop over 5 years. This mix helps explain why fresh earnings and Faizeon news are drawing attention to how sentiment around the stock may be shifting.

    Scan how Chemours fits into the broader AI infrastructure theme by comparing it with a curated set of 53 AI infrastructure stocks that are also chasing data center and high-performance computing demand.

    Bulls point to Chemours’ Q3 profit rebound and new Faizeon AI cooling fluids, while bears focus on multi year shareholder losses and prior net loss. Which story does the current valuation lean toward next?

    Most Popular Narrative: 19% Undervalued

    Chemours closed at $13.72, compared with an analyst consensus Narrative fair value of $16.90. This points to a material implied discount when set against the forecasts and risks that underpin that view in the analyst consensus Narrative on Simply Wall St.

    Execution on the Pathway to Thrive program, including guidance for adjusted EBITDA of US$775m to US$825m in 2026, a medium term target of at least US$1b adjusted EBITDA with more than 40% free cash flow conversion, and actions that have addressed close to US$2b of near term debt while aiming for net leverage around 3.8x, supports the case that Chemours can gradually improve earnings stability and free cash flow over time.

    See why 13 investors see Chemours as 19% undervalued.

    Result: Fair Value of $16.90 (UNDERVALUED)

    Still, Chemours carries unresolved PFAS litigation that could absorb more cash, and a softer refrigerant market may drag on Thermal & Specialized Solutions earnings.

    Find out about the key risks to this Chemours narrative.

    Next Steps

    Mixed feelings on Chemours after these updates. Act quickly, stress test the thesis against your own expectations, and balance the 3 key rewards and 2 important warning signs.

    Looking for more Chemours investment ideas?

    If Chemours has your attention today, do not stop here. Broader context across other opportunities can sharpen your judgment and help you avoid blind spots.